Agüloğlu Nurşin, Aksu Ayşegül, Unat Damla S, Akyol Murat
Department of Nuclear Medicine, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir.
Department of Nuclear Medicine, Başakşehir Çam and Sakura City Hospital, İstanbul.
Nucl Med Commun. 2022 Dec 1;43(12):1217-1224. doi: 10.1097/MNM.0000000000001625. Epub 2022 Oct 19.
The aim of this study is to determine the role of metabolic and volumetric parameters obtained from 18Fluorine-Fluorodeoxyglucose PET/computed tomography (18F-FDG PET/CT) imaging on progression-free survival (PFS) and overall survival (OS) in patients with advanced nonsquamous cell lung carcinoma (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement.
Pre and post-treatment PET/CT images of the ALK + NSCLC patients between January 2015 and July 2020 were evaluated. The highest standardized uptake value (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) values were obtained from pre-tyrosine kinase inhibitor (TKI) basal PET/CT (PETpre) and post-TKI PET/CT (PETpost) images. Total MTV (tMTV) and total TLG (tTLG) values were calculated by summing MTV and TLG values in all tumor foci. The change (Δ) in pSUVmax, pMTV, pTLG, tMTV and tTLG before and after treatment was calculated.The relationship of these parameters with OS and PFS was analyzed.
tTLGpre, tMTVpre, pTLGpre, pMTVpre, ∆SUVmax, ∆tMTV and ∆tTLG values were found to be associated with OS; ∆tMTV, ∆tTLG, tTLGpre, tMTVpre, pTLGpre and pMTVpre were associated with PFS. The cutoff values in both predicting OS and PFS were calculated as -31.6 and 391.1 for ∆tMTV and tTLGpre, respectively. In Cox regression analysis, ∆tMTV and stage for OS and ∆tMTV and tTLGpre for PFS were obtained as prognostic factors.
Metabolic and volumetric parameters, especially TLG values in the whole body before treatment and change in whole body MTV value, obtained from PET/CT may be useful in predicting prognosis and determining treatment strategies for patients with advanced ALK + NSCLC.
本研究旨在确定从18氟-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(18F-FDG PET/CT)成像中获得的代谢和体积参数对晚期非鳞状细胞肺癌(NSCLC)伴间变性淋巴瘤激酶(ALK)重排患者的无进展生存期(PFS)和总生存期(OS)的作用。
评估2015年1月至2020年7月期间ALK+NSCLC患者治疗前和治疗后的PET/CT图像。从酪氨酸激酶抑制剂(TKI)治疗前的基础PET/CT(PETpre)和TKI治疗后的PET/CT(PETpost)图像中获取最高标准化摄取值(SUVmax)、代谢肿瘤体积(MTV)和总病灶糖酵解(TLG)值。通过将所有肿瘤病灶的MTV和TLG值相加来计算总MTV(tMTV)和总TLG(tTLG)值。计算治疗前后pSUVmax、pMTV、pTLG、tMTV和tTLG的变化(Δ)。分析这些参数与OS和PFS的关系。
发现tTLGpre、tMTVpre、pTLGpre、pMTVpre、∆SUVmax、∆tMTV和∆tTLG值与OS相关;∆tMTV、∆tTLG、tTLGpre、tMTVpre、pTLGpre和pMTVpre与PFS相关。∆tMTV和tTLGpre预测OS和PFS的临界值分别计算为-31.6和391.1。在Cox回归分析中,获得∆tMTV和分期用于OS,∆tMTV和tTLGpre用于PFS作为预后因素。
从PET/CT获得的代谢和体积参数,尤其是治疗前全身的TLG值和全身MTV值的变化,可能有助于预测晚期ALK+NSCLC患者的预后并确定治疗策略。